公开(公告)号：US11028071B2

公开(公告)日：2021-06-08

申请号：US16924346

申请日：2020-07-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xiang-Yang Ye ,  Christian L. Morales ,  Mendi A. Higgins ,  Eric Mull

IPC: C07D401/14 ,  A61P35/00 ,  C07D471/04 ,  C07D498/04

Abstract: The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20190256496A1

公开(公告)日：2019-08-22

申请号：US16347831

申请日：2017-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xiang-Yang Ye ,  Christian L. Morales ,  Mendi Higgins ,  Eric Mull

IPC: C07D401/14 ,  C07D471/04 ,  C07D498/04 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20200339540A1

公开(公告)日：2020-10-29

申请号：US16924346

申请日：2020-07-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xiang-Yang Ye ,  Christian L. Morales ,  Mendi A. Higgins ,  Eric Mull

IPC: C07D401/14 ,  A61P35/00 ,  C07D471/04 ,  C07D498/04

Abstract: The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US10745384B2

公开(公告)日：2020-08-18

申请号：US16347831

申请日：2017-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xiang-Yang Ye ,  Christian L. Morales ,  Mendi A. Higgins ,  Eric Mull

IPC: C07D401/14 ,  A61P35/00 ,  C07D471/04 ,  C07D498/04 ,  A61K31/404

Abstract: The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.